Scholarlink

Purpose <p>This study aimed to investigate the impact of baseline nasal polyp score (NPS) on the effectiveness of dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).</p> Methods <p>In this retrospective observational study, 80 CRSwNP patients treated with dupilumab 300&#xa0;mg biweekly at a tertiary referral center were stratified according to the baseline NPS into two groups: low-NPS (&lt; 5) and high-NPS (≥ 5). Treatment outcomes were evaluated at the 6-month follow-up visit and compared.</p> Results <p>Both groups showed significant clinical improvements. The NPS decreased significantly in both low- and high-NPS groups, from a mean score of 3.2 to 0.8 and from 6.1 to 1.4, respectively (<i>p</i> &lt; 0.001 for both). SNOT-22 scores improved significantly in both groups (<i>p</i> &lt; 0.001 for both), though the reduction was greater in the high-NPS group (35.5 vs. 23.9, <i>p</i> = 0.018). There were no significant differences between low- and high NPS groups in proportions of NPS reduction of ≥ 1 (89% vs. 95%, <i>p</i> = 0.396) and clinically significant SNOT-22 improvement (= reduction &gt; 12 or follow-up SNOT &lt; 40; 80% vs. 86%, <i>p</i> = 0.544).</p> Conclusions <p>Our results suggests that dupilumab is effective in CRSwNP treatment, regardless of baseline nasal polyp size. Both small and large polyp groups showed significant improvements in NPS and patient-reported outcome measures. Future, prospective studies are warranted to validate these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical effectiveness of dupilumab in CRSwNP: unaffected by baseline nasal polyp size in real-world settings

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月20日

查看全文
  • Michael Habenbacher,
  • Ulrich Moser,
  • Ahmed Abaira,
  • Peter Kiss,
  • Clemens Holzmeister,
  • Jakob Pock,
  • Katharina Walla,
  • Angelika Lang,
  • Alexandros Andrianakis

摘要

Purpose

This study aimed to investigate the impact of baseline nasal polyp score (NPS) on the effectiveness of dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Methods

In this retrospective observational study, 80 CRSwNP patients treated with dupilumab 300 mg biweekly at a tertiary referral center were stratified according to the baseline NPS into two groups: low-NPS (< 5) and high-NPS (≥ 5). Treatment outcomes were evaluated at the 6-month follow-up visit and compared.

Results

Both groups showed significant clinical improvements. The NPS decreased significantly in both low- and high-NPS groups, from a mean score of 3.2 to 0.8 and from 6.1 to 1.4, respectively (p < 0.001 for both). SNOT-22 scores improved significantly in both groups (p < 0.001 for both), though the reduction was greater in the high-NPS group (35.5 vs. 23.9, p = 0.018). There were no significant differences between low- and high NPS groups in proportions of NPS reduction of ≥ 1 (89% vs. 95%, p = 0.396) and clinically significant SNOT-22 improvement (= reduction > 12 or follow-up SNOT < 40; 80% vs. 86%, p = 0.544).

Conclusions

Our results suggests that dupilumab is effective in CRSwNP treatment, regardless of baseline nasal polyp size. Both small and large polyp groups showed significant improvements in NPS and patient-reported outcome measures. Future, prospective studies are warranted to validate these findings.